| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | -0.0098 | 0.8 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |
| mRNA | Ko-143 | CTRPv2 | pan-cancer | AAC | -0.0092 | 0.8 |
| mRNA | SB52334 | GDSC1000 | pan-cancer | AAC | 0.009 | 0.8 |
| mRNA | navitoclax:piperlongumine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | Merck60 | CTRPv2 | pan-cancer | AAC | 0.0073 | 0.8 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | 0.0087 | 0.8 |
| mRNA | Elesclomol | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |